腹膜转移癌内科治疗新进展

黄莹莹,  赵赟博

downloadPDF
文章导航 > 中国肿瘤临床  > 2020 >  47(3): 123-127
黄莹莹, 赵赟博. 腹膜转移癌内科治疗新进展[J]. 中国肿瘤临床, 2020, 47(3): 123-127. doi: 10.3969/j.issn.1000-8179.2020.03.632
引用本文: 黄莹莹, 赵赟博. 腹膜转移癌内科治疗新进展[J]. 中国肿瘤临床, 2020, 47(3): 123-127. doi: 10.3969/j.issn.1000-8179.2020.03.632
shu
Yingying Huang, Yunbo Zhao. Progress on chemotherapy for peritoneal carcinomatosis[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(3): 123-127. doi: 10.3969/j.issn.1000-8179.2020.03.632
Citation: Yingying Huang, Yunbo Zhao. Progress on chemotherapy for peritoneal carcinomatosis[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(3): 123-127. doi: 10.3969/j.issn.1000-8179.2020.03.632
shu

腹膜转移癌内科治疗新进展

doi: 10.3969/j.issn.1000-8179.2020.03.632

  • 北京医院肿瘤内科, 国家老年医学中心(北京市 100730)

详细信息
    作者简介:

    黄莹莹  专业方向为消化道肿瘤及腹膜转移癌的化疗、靶向治疗及热疗。E-mail:xiaoyudianhh@126.com

    赵赟博，北京医院肿瘤内科主任医师，长期从事肿瘤内科的诊治和研究工作，尤其擅长消化道肿瘤的化疗、靶向治疗及免疫治疗，参与国内和国外多项临床研究，负责北京医院BSD-2000相控阵聚焦热疗。目前兼任中国老年学和老年医学学会老年肿瘤分会肿瘤心脏病专家委员会常委、中国临床肿瘤学会胃肠间质瘤专家委员会委员、中国临床肿瘤学会转化治疗专家委员会委员、中国抗癌协会老年肿瘤专业委员会委员、中国老年保健医学研究会老年胃肠外科分会委员、北京肿瘤学会结直肠肿瘤专业委员会委员、北京抗癌协会第一届大肠癌专业委员会常务委员、《肿瘤综合治疗电子杂志》第一届编辑委员会编委

    通讯作者:

    赵赟博, zhaoyb1206@163.com

Progress on chemotherapy for peritoneal carcinomatosis

  • Department of Oncology, Beijing Hospital, National Center of Gerontology, Beijing 100730, China

More Information

    摘要
  • 摘要: 腹膜转移癌因发现较晚且预后差，目前正成为研究热点。随着细胞减灭术及腹腔热灌注治疗的推广，部分经选择的患者获益。针对不同肿瘤的不同时期，大量的临床研究显示，用药选择、用药时机、用药方法方面均取得进展，尤其是加压腹腔内气溶胶化疗的使用减轻了治疗相关不良反应，并提高了疗效。本文就近年来腹膜转移癌的内科治疗进展进行阐述。

     

    Abstract: Peritoneal carcinomatosis is obtaining extensive attention because of its late detection and poor prognosis. Lately, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are widely used for the treatment of this condition and could be effective in some carefully selected patients. Different chemotherapies are combined with CRS or HIPEC, and different drug administration routes are used, such as intraperitoneal or pressurized intraperitoneal aerosol chemotherapy. Furthermore, the results of many clinical trials differed among patients with different types of cancer. Herein, we reviewed recent studies in patients with gastric, colon, and ovarian cancer to evaluate the progress of chemotherapy for peritoneal carcinomatosis.

     

    • HTML全文
    • 参考文献(28)
  • [1] Sampson JA. Implantation Peritoneal Carcinomatosis of Ovarian Origin[J]. Am J Pathol, 1931, 7(5):423-444. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_2062808
    [2] Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC:a systematic review of survival, mortality, and morbidity[J]. J Surg Oncol, 2011, 104(6):692-698. http://cn.bing.com/academic/profile?id=04ba216b512022f09344eb39566c3ea0&encoded=0&v=paper_preview&mkt=zh-cn
    [3] Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases:progress toward a new standard of care[J]. Cancer Treat Rev, 2016, 48:42-49. doi: 10.1016/j.ctrv.2016.06.007
    [4] Roviello F, Caruso S, Neri A, et al. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy:overview and rationale[J]. Eur J Surg Oncol, 2013, 39:1309-1316. http://cn.bing.com/academic/profile?id=6bcbdadaea4a455aa67ae8eca83c1ee1&encoded=0&v=paper_preview&mkt=zh-cn
    [5] Sun J, Song Y, Wang Z. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer:a meta-analysis of randomized controlled trials[J]. BMC Cancer, 2012, 12:526. doi: 10.1186/1471-2407-12-526
    [6] Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy:an innovative approach to treat peritoneal carcinomatosis[J]. World J Surg Oncol, 2016, 29(14):128. http://cn.bing.com/academic/profile?id=ee94fe438c6892fb40db1782f6477b3f&encoded=0&v=paper_preview&mkt=zh-cn
    [7] Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial:cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer[J]. Ann Surg Oncol, 2008, 15(9):2426-2432. doi: 10.1245/s10434-008-9966-2
    [8] Nagel JD, Varossieau FJ, Dubbelman R, et al. Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration[J]. Cancer Chemother Pharmacol, 1992, 29(6):480-484. doi: 10.1007/BF00684852
    [9] Elferink F, van der Vijgh WJ, Klein I, et al. Pharmacokinetics of carboplatin after intraperitoneal administration[J]. Cancer Chemother Pharmacol, 1988, 21(1):57-60. doi: 10.1007/BF00262740
    [10] Speyer JL, Collins JM, Dedrick RL, et al. Phase Ⅰ and pharmacological studies of 5-fluorouracil administered intraperitoneally[J]. Cancer Res, 1980, 40(3):567-572. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM7471076
    [11] Byrne RM, Gilbert EW, Dewey EN, et al. Who Undergoes Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Appendiceal Cancer?An Analysis of the National Cancer Database[J]. J Surg Res, 2019, 238:198-206. doi: 10.1016/j.jss.2019.01.039
    [12] Beckert S, Struller F, Grischke EM, et al. Surgical management of peritoneal surface malignancy with respect to tumour type, tumour stage and individual tumour biology[J]. Zentralbl Chir, 2016, 141:415-420. https://www.ncbi.nlm.nih.gov/pubmed/24241953
    [13] Minchinton AI, Tannock IF. Drug penetration in solid tumours[J]. Nat Rev Cancer, 2006, 6:583-592. doi: 10.1038/nrc1893
    [14] Imano M, Imamoto H, Itoh T, et al. Safety of intraperitoneal administration of paclitaxel after gastrectomy wih en-bloc D2 lymph node dissection[J]. J Surg Oncol, 2012, 105:43-47. doi: 10.1002/jso.22065
    [15] Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer:final results of a phase Ⅲ randomized clinical trial[J]. Ann Surg Oncol, 2011, 18:1575-81. doi: 10.1245/s10434-011-1631-5
    [16] Ishigami H, Fujiwara Y, Fukushima R, et al. Phase Ⅲ Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis:PHOENIX-GC Trial[J]. J Clin Oncol, 2018, 36(19):1922-1929. doi: 10.1200/JCO.2018.77.8613
    [17] Fugazzola P, Coccolini F, Montori G, et al. Overall and disease-free survival in patients treated with CRS+HIPEC with cisplatin and paclitaxel for gastric cancer with peritoneal carcinomatosis[J]. J Gastrointest Oncol, 2017, 8(3):572-582. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=9cda30d3-a3f1-47c0-9840-2d3c28ae7619
    [18] Naoto Ti, Mitsuro K, Takaki Y, et al. A randomized phase 2 multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence:final results of the INPACT trial[J]. J Gastri Ca, 2018, 21:1014-1023. doi: 10.1007/s10120-018-0817-y
    [19] Shinkai, M, Imano M, Chiba Y, et al.(2019)."Phase Ⅱ trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage ⅢA or ⅢB gastric cancer[J]. J Surg Oncol, 2019, 119(1):56-63.
    [20] Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis[J]. Semin Surg Oncol, 1998, 14:254-261. doi: 10.1002-(SICI)1098-2388(199804-05)14-3%26lt%3b254--AID-SSU10%26gt%3b3.0.CO%3b2-U/
    [21] Sugarbaker PH. Management of peritoneal-surface malignancy:the surgeon's role[J]. Langenbecks Arch Surg, 1999, 384:576-587. doi: 10.1007/s004230050246
    [22] Sugarbaker PH. Carcinomatosis——is cure an option[J]. J Clin Oncol, 2003, 21:762-764. doi: 10.1200/JCO.2003.12.071
    [23] Quenet F, Elias D, Roca L, et al. A UNICANCER phase Ⅲ trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC):PRODIGE[J]. J Clin Oncol, 2018, 36:18.
    [24] Sgarbura O, Hübner M, Alyami M, et al. Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective:A multicenter study[J]. Eur J Surg Oncol, 2019, pii:S0748-7983. http://cn.bing.com/academic/profile?id=9a382c8c15d4bfd8769687b84c088f3c&encoded=0&v=paper_preview&mkt=zh-cn
    [25] Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin[J]. J Clin Oncol, 2009, 27:681-685. doi: 10.1200/JCO.2008.19.7160
    [26] van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer[J]. NEJM, 2018, 378(3):230-240. doi: 10.1056/NEJMoa1708618
    [27] Claudia M, Francesca DF, Giorgia P, et al. Role of intraperitoneal chemotherapy in ovarian cancer in the platinumtaxane-based era:a metaanalysis[J]. Critic Rev Oncol/Hemat, 2019, 136:64-69. doi: 10.1016/j.critrevonc.2019.01.002
    [28] Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era:a meta-analysis[J]. J Clin Oncol, 2002, 20(5):1248-1259. http://cn.bing.com/academic/profile?id=957416a01815844e09352f89db7b7f91&encoded=0&v=paper_preview&mkt=zh-cn
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  179
  • HTML全文浏览量:  32
  • PDF下载量:  19
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-07-03
  • 刊出日期:  2020-02-15

目录

    /

    返回文章
    返回

    版权所有 © 2013《中国肿瘤临床》编辑部津ICP备09011441号-3

    地址：天津市河西区体院北环湖西路肿瘤医院内 300060电话/传真：(022)23527053Email：cjco@cjco.cn

    本系统由北京仁和汇智信息技术有限公司开发    百度统计